TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04931342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
Study: NCT06740630

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 20
Description: The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxneuvance
Description: The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxneuvance
Description: The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Study: NCT04931342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib will be administered by mouth twice a day during each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle
Study: NCT05659420

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor
Description: aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor
Description: aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor
Description: aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
Study: NCT04931342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle
Study: NCT05280483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021 with fed state
Description: 25 mg ABSK021 (1x25 mg ABSK021 capsule) with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021 with fasted state
Description: 25 mg ABSK021 (1x25 mg ABSK021 capsule) without food
Study: NCT05806671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 320mg/day orally continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle
Study: NCT05770531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection for banking

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection for ctDNA evaluation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given by IV
Study: NCT05857228

Intervention type: PROCEDURE
Intervention: Endoscopic sinus surgery (ESS)
Description: Endoscopic sinus surgery for removal of nasal polyps and sinus tissue.
Study: NCT04819672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Training associated with Partial Blood Flow
Description: 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low Intensity Training associated with Partial Blood Flow-Sham
Description: 16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
Study: NCT04889703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% Trichloroacetic acid peel
Description: Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments at 4 week intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% Salicylic acid peel
Description: Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
Study: NCT06075615

Intervention type: DRUG
Intervention: dacomitnib
Description: patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
Study: NCT04931342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Description: LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Description: LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle
Study: NCT06560801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Randomization will take place at visit 1 to either the group receiving standard care and dapagliflozin or standard care only.
Study: NCT04757220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive tasks with EEG recording
Description: questionnaires and cognitives tasks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive tasks with EEG recording
Description: questionnaires and cognitives tasks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive tasks with EEG recording
Description: questionnaires and cognitives tasks
Study: NCT05387603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 177Lu-DOTATOC
Description: The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
Study: NCT06533553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole Dihydrochloride
Description: Administration of dexpramipexole tablet
Study: NCT05997797

Intervention type: OTHER
Intervention: FAAM
Description: The FAAM is made out of two subscales including ADL and Sports subscales that have a complete score of 84 and 32, individually
Study: NCT06046820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INZ-701
Description: Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm (Conventional Therapy)
Description: Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.
Study: NCT06218394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microneedling
Description: The microneedling technique (Electric microneedle, F6, China Bohui Meicui Bioengineering Technology Guangzhou Co., LTD.) performed in the targeted areas using a sterile micro needles stamp. In this study, the needle length was adjusted to 0.7\~1 mm according to the grade of hair loss and the degree of tolerance of the patient. Before microneedling treatment, the scalp was disinfected with 75% alcohol, and then 1 ml of nutritional dressing for the scalp was applied externally, and the microneedle pen was gently touched to the scalp vertically for pricking. Patients are instructed to refrain from shampooing, warm baths, and strenuous exercise for 8 hours after treatment. Each patient was treated by microneedling once every 2 weeks for a total of 12 treatments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Concentrated Growth Factor
Description: 1. 27\~36ml of autologous venous blood is collected in a sterile Vacuette tube without anticoagulant solution, and centrifuged by Medifuge variable speed centrifuge (Silfradent company, Italy) for about 13min (accelerated for 30s; 2700 r/min, 2 min; 2400 r/min, 4min; 2700r/min, 4min; 3300r/min, 3 min; decelerated for 36s to stop). The lowest layer retains 2.5ml of CGF per 9ml of venous blood.~2. The scalp is cleaned, disinfected and anesthetized, CGF is extracted with a 2.5ml syringe, and the disposable sterile needle roller handle is slowly rolled in the hair loss area, and the CGF is applied to the corresponding scalp part for introduction treatment while rolling, and the force is uniform and stable, repeating back and forth several times, to the extent that the patient can tolerate and the skin in the treatment area is slightly red. The operation time is about 15\~20 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% minoxidil
Description: topical 5% minoxidil, 1 ml, once daily
Study: NCT04968821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Participants randomized to the physical activity intervention will receive a Fitbit and be enrolled in Fitabase (Fitbit tracking system). Participants will also participate in 8 tele-health sessions with a physical therapist. Sessions will involve setting weekly physical activity goals and reviewing the participant's physical activity on the Fitbit tracking system.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual postoperative care includes surgeon-directed lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
Study: NCT06429592

Intervention type: OTHER
Intervention: education
Description: nursing care practice

Intervention type: OTHER
Intervention: education
Description: nursing care practice
Study: NCT06559085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laproscopic posterior mesh rectopexy (Wells or LPMR)
Description: After complete rectal mobilization, a mesh is inserted between the sacrum and the posterior rectum, sutured into the rectum, and fixed to the promontory. The mortality rates ranged from 0% to 1.2%, and recurrence rates ranged from 0% to 11% There was an overall improvement in continence (74%-100%), with conflicting results regarding constipation. New-onset constipation in 5% to 44% of patients was reported

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic lateral mesh rectopexy (Orr-Loygue)
Description: This procedure involves complete mobilization of the rectum with two mesh strips sutured laterally to the rectal wall on both sides, and they were suspended to the promontory. There are several studies on this procedure using a laparoscopic approach. Lechaux et al. performed laparoscopic Orr-Loygue rectopexy in 35 patients. Incontinence improved in 27% of patients, and constipation improved in 19% but worsened in 27%. The recurrence rate was 3% (1/35) after a mean follow-up of 36 months. A study on 46 patients with laparoscopic Orr-Loygue procedure with posterior mobilization found a significant reduction in incontinence score after 1 year, but there were no changes in the use of laxatives. The recurrence rate was 4% after a median follow-up of 1.5 years
Study: NCT05329922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALICE: Audiological rehabilitation
Description: Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALICE: Audiological rehabilitation
Description: Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.
Study: NCT06046430

Intervention type: OTHER
Intervention: Assessment
Description: The same assessments will be made to participants in both groups.

Intervention type: OTHER
Intervention: Assessment
Description: The same assessments will be made to participants in both groups.
Study: NCT06561035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opiate Sparing
Description: Subjects will receive medications in the Opiate Sparing arm for pain control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opiate Based
Description: Subjects will receive medications in the Opiate Based arm for pain control.
Study: NCT06524219

Intervention type: PROCEDURE
Intervention: unilateral intrafascial resection
Description: Conducting unilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy

Intervention type: PROCEDURE
Intervention: bilateral intrafascial resection
Description: Conducting bilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy

Intervention type: PROCEDURE
Intervention: bilateral extrafascial resection
Description: Conducting bilateral extrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
Study: NCT05698589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Focused Therapy
Description: CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, ...) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, ...). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ending Self Stigma
Description: Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals